1. The orally administered pharmaceutical composition comprising α, α, α-triftortimidin and 5-chloro-6- (2-iminopirrolidin-1-yl) methyl-2,4 (1H, 3H) -pyrimidine dione hydrochloride as active ingredients and sugar having a critical relative humidity of 85% or more at 25 ° C, as ekstsepienta.2. Orally administered pharmaceutical composition according to Claim. 1, where the sugar content, having a critical relative humidity of 85% or more at 25 ° C, is 3.6 parts by weight or more based on 1 part by weight of α, α, α-triftortimidina.3 . Orally administered pharmaceutical composition according to Claim. 1, wherein the sugar having a critical relative humidity of 85% or more at 25 ° C, a disaccharide or a sugar spirtom.4. Orally administered pharmaceutical composition according to Claim. 1, wherein the sugar having a critical relative humidity of 85% or more at 25 ° C, is one or more selected from lactose, sucrose, mannitol and eritritola.5. Orally administered pharmaceutical composition according to claim 1, soderzhaschayatriftortimidin and 5-chloro-6- (2-iminopirrolidin-1-yl) methyl-2,4 (1H, 3H) -pyrimidine dione hydrochloride in a molar ratio of 1:. 0,5.6. Orally administered pharmaceutical composition according to Claim. 1, comprising one or more selected from low substituted hydroxypropyl cellulose, carmellose, corn starch, partially pregelatinized starch, and crospovidone as disintegrant sredstva.7. An oral pharmaceutical composition according to claim. 6, wherein the content of disintegrating agent is from 2 to 16% by weight in the total amount of the pharmaceutical kompozitsii.8. An oral pharmaceutical composition according to Claim. 1, wherein the pharmaceutical composition is in the form of granules, the product obtained by the Pres1. Перорально вводимая фармацевтическая композиция, содержащая α,α,α-трифтортимидин и 5-хлор-6-(2-иминопирролидин-1-ил) метил-2,4 (1H,3H)-пиримидин дион гидрохлорид в качестве активных ингредиентов и сахар, имеющий критическую относит
